Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Open accessThe DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases represent nowadays one of the major health problems. Despite the efforts made to unveil the mechanism leading to neurodegeneration, it is still not entirely clear what triggers this phenomenon and what allows its progression. Nevertheless, it is accepted that neurodegeneration is a consequence of several detrimental processes, such as protein aggregation, oxidative stress, and neuroinflammation, finally resulting in the loss of neuronal functions. Starting from these evidences, there has been a wide search for novel agents able to address more than a single event at the same time, the so‐called multitarget‐directed ligands (MTDLs). These compounds originated from the combination of different pharmacophoric elements which endowed them with the ability to interfere with different enzymatic and/or receptor systems, or to exert neuroprotective effects by modulating proteins and metal homeostasis. MTDLs have been the focus of the latest strategies to discover a new treatment for Alzheimer’s disease (AD), which is considered the most common form of dementia characterized by neurodegeneration and cognitive dysfunctions. This review is aimed at collecting the latest and most interesting target combinations for the treatment of AD, with a detailed discussion on new agents with favorable in vitro properties and on optimized structures that have already been assessed in vivo in animal models of dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Given the multifactorial nature of AD523”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [523]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 1×
“Amongst the latter, the Fatty Acid Amide Hydrolase (FAAH) was originally identified as the enzyme responsible for AEA hydrolysis [96] while the Monoacylglycerol Lipase (MGL) plays a pivotal role in the regulation of 2-AG levels [97].”
BackgroundBrown, R. H., & Al-Chalabi, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1603471 · Cited by 2,125
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644 · cited 1×
“In particular, HDAC2 and HDAC3 have a critical role in controlling memory-related genes [120], while dampening HDAC6 activity enhances pTAU and Aβ clearance [121– 122].”
BackgroundAlzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009
An epigenetic blockade of cognitive functions in the neurodegenerating brain
Gräff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., et al. (2012) · Nature · doi:10.1038/nature10849 · Cited by 853
Mitochondria, oxidative stress and neurodegeneration
Federico, A., Cardaioli, E., Da Pozzo, P., Formichi, P., Gallus, G. N., & Radi, E. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.05.030 · Cited by 787
Mitochondrial Defects and Oxidative Stress in Alzheimer Disease and Parkinson Disease
Yan, M. H., Wang, X., & Zhu, X. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.11.014 · Cited by 718 · cited 1×
“This oxidative stress is caused by various underlying factors such as mitochondrial dysfunction [9, 10], dyshomeostasis of metal ions (e.”
BackgroundProtein misfolding in neurodegenerative diseases: Implications and strategies
Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell, A., Leblanc, G., Venkateswaran, A., Nurmi, A., et al. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0077-5 · Cited by 675 · cited 1×
“formed out of aggregated Aβ fibrils and neurofibrillary tangles (NFTs) made of hyperphosphorylated TAU protein (pTAU) [4].”
Backgroundα-Synuclein misfolding and Parkinson's disease
Breydo, L., Wu, J. W., & Uversky, V. N. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.002 · Cited by 657
Benito, C., Núñez, E., Tolón, R. M., Carrier, E. J., Rábano, A., Hillard, C. J., & Romero, J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11136.2003 · Cited by 624
Oxidative stress hypothesis in Alzheimer’s disease: a reappraisal
Praticò, D. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.09.001 · Cited by 606 · cited 1×
“Thus, oxidation of the main constituents of neurons (lipids, proteins, and nucleic acids) leads invariably to neurodegeneration [8].”
BackgroundStructure, function, and allosteric modulation of NMDA receptors
Hansen, K. B., Yi, F., Perszyk, R. E., Furukawa, H., Wollmuth, L. P., Gibb, A. J., & Traynelis, S. F. (2018) · Journal of General Physiology · doi:10.1085/jgp.201812032 · Cited by 573
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 1×
“They proposed hybrid compounds merging the metal ion chelating framework of chloroquine and the key binding site fragments of the known PDE4 inhibitors Rolipram and Roflumilast, already tested in preclinical models of AD [132] (see also NCT01433666 and NCT02051335).”
BackgroundMetal dyshomeostasis and oxidative stress in Alzheimer’s disease
Greenough, M. A., Camakaris, J., & Bush, A. I. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.014 · Cited by 436
Untangling Amyloid-β, Tau, and Metals in Alzheimer’s Disease
Savelieff, M. G., Lee, S., Liu, Y., & Lim, M. H. (2013) · ACS Chemical Biology · doi:10.1021/cb400080f · Cited by 400
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
Energetics of Functional Activation in Neural Tissues
Sokoloff, L. (1999) · Neurochemical Research · doi:10.1023/a:1022534709672 · Cited by 373
Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., Moxham, T., Davis, S., Thokala, P., Wailoo, A., et al. (2012) · Health Technology Assessment · doi:10.3310/hta16210 · Cited by 308
The histamine H3receptor: an attractive target for the treatment of cognitive disorders
Esbenshade, T. A., Browman, K. E., Bitner, R. S., Strakhova, M., Cowart, M. D., & Brioni, J. D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.147 · Cited by 296
Endocannabinoids and the regulation of their levels in health and disease
Di Marzo, V., & Petrosino, S. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32803dbdec · Cited by 289
The serotonergic system and cognitive function
Švob Štrac, D., Pivac, N., & Mück-Šeler, D. (2016) · Translational Neuroscience · doi:10.1515/tnsci-2016-0007 · Cited by 285
Amyloid–cholinesterase interactions: Implications for Alzheimer’s disease
Inestrosa, N. C., Dinamarca, M. C., & Alvarez, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.06238.x · Cited by 261
PARP-1 involvement in neurodegeneration: A focus on Alzheimer’s and Parkinson’s diseases
Martire, S., Mosca, L., & d’Erme, M. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.04.001 · Cited by 235
Wang, Y.-Q., Wang, P.-Y., Wang, Y.-T., Yang, G.-F., Zhang, A., & Miao, Z.-H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00055 · Cited by 235
Schedin-Weiss, S., Inoue, M., Hromadkova, L., Teranishi, Y., Yamamoto, N. G., Wiehager, B., Bogdanovic, N., Winblad, B., Sandebring-Matton, A., Frykman, S., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0279-1 · Cited by 230
Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases
Ryskamp, D. A., Korban, S., Zhemkov, V., Kraskovskaya, N., & Bezprozvanny, I. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00862 · Cited by 217
The endocannabinoid system: an overview
Battista, N., Di Tommaso, M., Bari, M., & Maccarrone, M. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2012.00009 · Cited by 213
Brioni, J. D., Esbenshade, T. A., Garrison, T. R., Bitner, S. R., & Cowart, M. D. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166876 · Cited by 203
Targeting HDACs: A Promising Therapy for Alzheimer's Disease
Xu, K., Dai, X.-L., Huang, H.-C., & Jiang, Z.-F. (2011) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2011/143269 · Cited by 202
Oxidative Stress in Alzheimer’s Disease: Are We Connecting the Dots?: Miniperspective
Rosini, M., Simoni, E., Milelli, A., Minarini, A., & Melchiorre, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400970m · Cited by 201
Tubastatin A/ACY-1215 Improves Cognition in Alzheimer's Disease Transgenic Mice
Zhang, L., Liu, C., Wu, J., Tao, J.-J., Sui, X.-L., Yao, Z.-G., Xu, Y.-F., Huang, L., Zhu, H., Sheng, S.-L., et al. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-140066 · Cited by 192
Acetylcholinesterase Inhibition in Alzheimers Disease
Ibach, B., & Haen, E. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043386509 · Cited by 190
Alzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms
von Bernhardi, R., & Eugenín, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4082 · Cited by 190
Monoamine Oxidase B Inhibitors in Parkinson's Disease
Dezsi, L., & Vecsei, L. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170124165222 · Cited by 188
Crystal Structure of the Human Monoacylglycerol Lipase, a Key Actor in Endocannabinoid Signaling
Labar, G., Bauvois, C., Borel, F., Ferrer, J., Wouters, J., & Lambert, D. M. (2010) · ChemBioChem · doi:10.1002/cbic.200900621 · Cited by 185
The Histamine H3 Receptor: Structure, Pharmacology, and Function
Nieto-Alamilla, G., Márquez-Gómez, R., García-Gálvez, A.-M., Morales-Figueroa, G.-E., & Arias-Montaño, J.-A. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104752 · Cited by 185
Ismaili, L., Refouvelet, B., Benchekroun, M., Brogi, S., Brindisi, M., Gemma, S., Campiani, G., Filipic, S., Agbaba, D., Esteban, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.003 · Cited by 178
Self-citationScott, J. D., Li, S. W., Brunskill, A. P. J., Chen, X., Cox, K., Cumming, J. N., Forman, M., Gilbert, E. J., Hodgson, R. A., Hyde, L. A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00307 · Cited by 174
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
Coimbra, J. R. M., Marques, D. F. F., Baptista, S. J., Pereira, C. M. F., Moreira, P. I., Dinis, T. C. P., Santos, A. E., & Salvador, J. A. R. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00178 · Cited by 171
Scott Bitner, R. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.009 · Cited by 162
Calcium channel blockers and dementia
Nimmrich, V, & Eckert, A. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12240 · Cited by 155
Hutson, P. H., Finger, E. N., Magliaro, B. C., Smith, S. M., Converso, A., Sanderson, P. E. J., Mullins, D. E., Hyde, L. A., Eschle, B. K., Turnbull, Z., et al. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.009 · Cited by 146
Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Cai, Z., Zhao, Y., & Zhao, B. (2012) · Current Alzheimer Research · doi:10.2174/156720512802455386 · Cited by 145
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
Unzeta, M., Esteban, G., Bolea, I., Fogel, W. A., Ramsay, R. R., Youdim, M. B. H., Tipton, K. F., & Marco-Contelles, J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00205 · Cited by 144
Zhang, X., Rakesh, K. P., Bukhari, S. N. A., Moku, B., Manukumar, H. M. G., & Qin, H. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.06.009 · Cited by 142
Jeppsson, F., Eketjäll, S., Janson, J., Karlström, S., Gustavsson, S., Olsson, L.-L., Radesäter, A.-C., Ploeger, B., Cebers, G., Kolmodin, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.409110 · Cited by 139
Sivaprakasam, P., Han, X., Civiello, R. L., Jacutin-Porte, S., Kish, K., Pokross, M. E., Lewis, H. A., Ahmed, N., Szapiel, N., Newitt, J. A., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.03.046 · Cited by 135
Histone Deacetylase-1 (HDAC1) Is a Molecular Switch between Neuronal Survival and Death
Bardai, F. H., Price, V., Zaayman, M., Wang, L., & D'Mello, S. R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394544 · Cited by 134
Serotonin: A New Hope in Alzheimer’s Disease?
Claeysen, S., Bockaert, J., & Giannoni, P. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00135 · Cited by 133
Lecoutey, C., Hedou, D., Freret, T., Giannoni, P., Gaven, F., Since, M., Bouet, V., Ballandonne, C., Corvaisier, S., Malzert Fréon, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410315111 · Cited by 133
Jung, K.-M., Astarita, G., Yasar, S., Vasilevko, V., Cribbs, D. H., Head, E., Cotman, C. W., & Piomelli, D. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.012 · Cited by 133
Acetylation: a new key to unlock tau’s role in neurodegeneration
Cook, C., Stankowski, J. N., Carlomagno, Y., Stetler, C., & Petrucelli, L. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt259 · Cited by 132
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
Bilir, C., & Sarısözen, C. (2017) · Journal of Oncological Sciences · doi:10.1016/j.jons.2017.04.001 · Cited by 130
Avila, J., Wandosell, F., & Hernández, F. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.40 · Cited by 129
Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129 · cited 1×
“Donecopride [79] is an AChE inhibitor with partial 5-HT4R agonist activity inspired by the 5-HT4R agonist RS67333 (29, Figure 10), which showed in vivo procognitive and antiamnesic effects in NMRI mice and promoted sAPPα release in C57BL/6 mice [80].”
BackgroundSelf-citationLoss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation
Cook, C., Gendron, T. F., Scheffel, K., Carlomagno, Y., Dunmore, J., DeTure, M., & Petrucelli, L. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds125 · Cited by 128
Curcumin and Resveratrol in the Management of Cognitive Disorders: What is the Clinical Evidence?
Mazzanti, G., & Di Giacomo, S. (2016) · Molecules · doi:10.3390/molecules21091243 · Cited by 127
Bonda, D. J., Mailankot, M., Stone, J. G., Garrett, M. R., Staniszewska, M., Castellani, R. J., Siedlak, S. L., Zhu, X., Lee, H.-G., Perry, G., et al. (2010) · Redox Report · doi:10.1179/174329210x12650506623645 · Cited by 124
Jiang, X.-Y., Chen, T.-K., Zhou, J.-T., He, S.-Y., Yang, H.-Y., Chen, Y., Qu, W., Feng, F., & Sun, H.-P. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00463 · Cited by 122 · cited 1×
“From the combination of a known GSK-3β inhibitor [39] and the THA moiety as AChE binder, some thiazole-based compounds were synthesized (18, Figure 6) with the potential to be a novel class of dual GSK-3β/AChE [40].”
BackgroundNguyen, L., Lucke-Wold, B. P., Mookerjee, S., Kaushal, N., & Matsumoto, R. R. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-50174-1_10 · Cited by 118
Role of Serotonin in Alzheimerʼs Disease: A New Therapeutic Target?
Geldenhuys, W. J., & Van der Schyf, C. J. (2011) · CNS Drugs · doi:10.2165/11590190-000000000-00000 · Cited by 117 · cited 1×
“Hence, the modulation of specific 5-HTR subtypes could represent a major therapeutic strategy in the fight against AD [73].”
BackgroundAn NMDA Receptor Signaling Complex with Protein Phosphatase 2A
Chan, S. F., & Sucher, N. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-20-07985.2001 · Cited by 108
Cuadrado‐Tejedor, M., García, C., Sánchez-Arias, J. A., Rabal, O., Pérez-González, M., Mederos, S., Ugarte, A., Franco, R., Segura, V., Perea, G., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.163 · Cited by 108
Alzheimer's disease: Pathogenesis and prevention
Braak, H., & Del Tredici, K. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.01.011 · Cited by 105
Butyrylcholinesterase and the cholinergic system
Reid, G. A., Chilukuri, N., & Darvesh, S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.054 · Cited by 105 · cited 1×
“Butyrylcholineterase (BuChE) also plays an important role in cholinergic mediation [28].”
BackgroundUse of Peptides for the Management of Alzheimer’s Disease: Diagnosis and Inhibition
Baig, M. H., Ahmad, K., Rabbani, G., & Choi, I. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00021 · Cited by 104
5-HT6 receptors and Alzheimer's disease
Ramírez, M. J. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt169 · Cited by 102
Sharma, P., Tripathi, A., Tripathi, P. N., Prajapati, S. K., Seth, A., Tripathi, M. K., Srivastava, P., Tiwari, V., Krishnamurthy, S., & Shrivastava, S. K. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.030 · Cited by 98
Hagena, H., & Manahan-Vaughan, D. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.06.014 · Cited by 97
One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug
Hughes, R. E., Nikolic, K., & Ramsay, R. R. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00177 · Cited by 93
Candore, G., Bulati, M., Caruso, C., Castiglia, L., Colonna-Romano, G., Di Bona, D., Duro, G., Lio, D., Matranga, D., Pellicanò, M., et al. (2010) · Rejuvenation Research · doi:10.1089/rej.2009.0993 · Cited by 92
Souza, L. C., Jessé, C. R., Antunes, M. S., Ruff, J. R., Janner, D. E., Gomes, N. S., Donato, F., Giacomeli, R., & Boeira, S. P. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.03.002 · Cited by 92
Yazdani, M., Edraki, N., Badri, R., Khoshneviszadeh, M., Iraji, A., & Firuzi, O. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.11.038 · Cited by 92
Wang, Z., Hu, J., Yang, X., Feng, X., Li, X., Huang, L., & Chan, A. S. C. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01417 · Cited by 91 · cited 1×
“A very detailed research involving several quinolineindole-based derivatives pointed out the ability of these compounds in promoting cell proliferation in the adult murine hippocampus, as a result of their neuroprotective effect against Aβ-related toxicity and oxidative stress [138].”
BackgroundKodis, E. J., Choi, S., Swanson, E., Ferreira, G., & Bloom, G. S. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.05.017 · Cited by 89
Sang, Z., Wang, K., Zhang, P., Shi, J., Liu, W., & Tan, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.021 · Cited by 89
Borroni, E., Bohrmann, B., Grueninger, F., Prinssen, E., Nave, S., Loetscher, H., Chinta, S. J., Rajagopalan, S., Rane, A., Siddiqui, A., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241653 · Cited by 86
Iraji, A., Firuzi, O., Khoshneviszadeh, M., Tavakkoli, M., Mahdavi, M. R., Nadri, H., Edraki, N., & Miri, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.057 · Cited by 86
Montanari, S., Scalvini, L., Bartolini, M., Belluti, F., Gobbi, S., Andrisano, V., Ligresti, A., Di Marzo, V., Rivara, S., Mor, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00609 · Cited by 83
Xu, Y., Wang, H., Li, X., Dong, S., Liu, W., Gong, Q., Wang, T., Tang, Y., Zhu, J., Li, J., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.025 · Cited by 80
PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition
Kroker, K. S., Mathis, C., Marti, A., Cassel, J., Rosenbrock, H., & Dorner‐Ciossek, C. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.023 · Cited by 75
5-HT4 receptor and Alzheimer's disease: The amyloid connection
Lezoualc’h, F. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.02.001 · Cited by 72
The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease
Mesiti, F., Chavarria, D., Gaspar, A., Alcaro, S., & Borges, F. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111572 · Cited by 72
Iraji, A., Firuzi, O., Khoshneviszadeh, M., Nadri, H., Edraki, N., & Miri, R. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.01.017 · Cited by 71
Röhrig, U. F., Majjigapu, S. R., Chambon, M., Bron, S., Pilotte, L., Colau, D., den Eynde, B. J. V., Turcatti, G., Vogel, P., Zoete, V., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.06.078 · Cited by 70
Cuadrado-Tejedor, M., Garcia-Barroso, C., Sanzhez-Arias, J., Mederos, S., Rabal, O., Ugarte, A., Franco, R., Pascual-Lucas, M., Segura, V., Perea, G., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0142-9 · Cited by 69 · cited 1×
“Previously, a cocktail of two different drugs acting on these two enzymes (Vorinostat and Tadalafil) gave in vivo positive effects, by alleviating cognitive deficits in AD mice and by reversing the reduced density of hippocampal neurons [125].”
BackgroundMemantine ER/Donepezil: A Review in Alzheimer’s Disease
Greig, S. L. (2015) · CNS Drugs · doi:10.1007/s40263-015-0287-2 · Cited by 69
Kaur, A., Mann, S., Kaur, A., Priyadarshi, N., Goyal, B., Singhal, N. K., & Goyal, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.058 · Cited by 69
Peptides as Potential Therapeutics for Alzheimer’s Disease
Ribarič, S. (2018) · Molecules · doi:10.3390/molecules23020283 · Cited by 67
Oukoloff, K., Coquelle, N., Bartolini, M., Naldi, M., Le Guevel, R., Bach, S., Josselin, B., Ruchaud, S., Catto, M., Pisani, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.063 · Cited by 65
Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors
Gabr, M. T., & Abdel-Raziq, M. S. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.06.031 · Cited by 63
Self-citationHEPATOTOXICITY OF TETRAHYDROACRIDINE
Ames, D. J., Bhathal, P. S., Davies, B. M., & Fraser, J. R. E. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91636-4 · Cited by 61
Roles of sigma-1 receptors in Alzheimer's disease.
Jin, J., Fang, M., Zhao, Y., & Liu, X. (2015) · PubMed · Cited by 61
Sang, Z., Wang, K., Shi, J., Liu, W., & Tan, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.026 · Cited by 59
De Simone, A., La Pietra, V., Betari, N., Petragnani, N., Conte, M., Daniele, S., Pietrobono, D., Martini, C., Petralla, S., Casadei, R., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00507 · Cited by 56
Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer’s Disease
Więckowska, A., Wichur, T., Godyń, J., Bucki, A., Marcinkowska, M., Siwek, A., Więckowski, K., Zaręba, P., Knez, D., Głuch‐Lutwin, M., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00024 · Cited by 55
Brogi, S., Butini, S., Maramai, S., Colombo, R., Verga, L., Lanni, C., Lorenzi, E. D., Lamponi, S., Andreassi, M. G., Bartolini, M., et al. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12290 · Cited by 53
Self-citationHu, J., Pan, T., An, B., Li, Z., Li, X., & Huang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.013 · Cited by 53
Lalut, J., Santoni, G., Karila, D., Lecoutey, C., Davis, A., Nachon, F., Silman, I., Sussman, J., Weik, M., Maurice, T., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.064 · Cited by 52
5HT6 antagonists in the treatment of Alzheimer's dementia: current progress
Andrews, M., Tousi, B., & Sabbagh, M. N. (2018) · Neurology and Therapy · doi:10.1007/s40120-018-0095-y · Cited by 50
Chioua, M., Buzzi, E., Moraleda, I., Iriepa, I., Maj, M., Wnorowski, A., Giovannini, C., Tramarin, A., Portali, F., Ismaïli, L., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.06.044 · Cited by 50
Yahiaoui, S., Hamidouche, K., Ballandonne, C., Davis, A., Santos, J. S. O., Fréret, T., Boulouard, M., Rochais, C., & Dallemagne, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.048 · Cited by 49
Self-citationButini, S., Brindisi, M., Brogi, S., Maramai, S., Guarino, E., Panico, A., Saxena, A., Chauhan, V. P. S., Colombo, R., Verga, L., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4002908 · Cited by 48
Self-citationDownregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease
Theendakara, V. P., Bredesen, D. E., & Rao, R. V. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.07.002 · Cited by 48
Novel Multitarget Directed Triazinoindole Derivatives as Anti-Alzheimer Agents
Patel, D. V., Patel, N. R., Kanhed, A. M., Patel, S. P., Sinha, A., Kansara, D. D., Mecwan, A. R., Patel, S. B., Upadhyay, P. N., Patel, K. B., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00226 · Cited by 48
Francis, P. T., Parsons, C. G., & Jones, R. W. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.124 · Cited by 45
Yu, Y.-F., Huang, Y.-D., Zhang, C., Wu, X.-N., Zhou, Q., Wu, D., Wu, Y., & Luo, H. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00268 · Cited by 44
Wang, D., Hu, M. S., Li, X., Zhang, D., Chen, C., Fu, J., Shao, S., Shi, G., Zhou, Y., Wu, S., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.053 · Cited by 43
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington’s Disease
Mazarei, G., & Leavitt, B. R. (2015) · Journal of Huntington's Disease · doi:10.3233/jhd-159003 · Cited by 40
Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases
Butini, S., Brindisi, M., Gemma, S., Minetti, P., Cabri, W., Gallo, G., Vincenti, S., Talamonti, E., Borsini, F., Caprioli, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300689c · Cited by 38
Self-citationHatat, B., Yahiaoui, S., Lecoutey, C., Davis, A., Fréret, T., Boulouard, M., Claeysen, S., Rochais, C., & Dallemagne, P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00148 · Cited by 38
Self-citationPérez-Areales, F. J., Turcu, A. L., Barniol-Xicota, M., Pont, C., Pivetta, D., Espargaró, A., Bartolini, M., De Simone, A., Andrisano, V., Pérez, B., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.051 · Cited by 38
Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model
Soudy, R., Kimura, R., Patel, A., Fu, W., Kaur, K., Westaway, D. A., Yang, J., & Jhamandas, J. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-47255-9 · Cited by 38
Lü, X., He, S.-Y., Li, Q., Yang, H., Jiang, X., Lin, H., Chen, Y., Qu, W., Feng, F., Bian, Y., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.02.014 · Cited by 37
Roldán-Peña, J. M., Romero-Real, V., Hicke, J., Maya, I., Franconetti, A., Lagunes, I., Padrón, J. M., Petralla, S., Poeta, E., Naldi, M., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.053 · Cited by 36
Kołaczkowski, M., Marcinkowska, M., Bucki, A., Śniecikowska, J., Pawłowski, M., Kazek, G., Siwek, A., Jastrzębska‐Więsek, M., Partyka, A., Wasik, A., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.045 · Cited by 34
Kaur, A., Narang, S. S., Kaur, A., Mann, S., Priyadarshi, N., Goyal, B., Singhal, N. K., & Goyal, D. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00168 · Cited by 34
Huang, M., Shao, Y., Hou, J., Cui, W., Liang, B., Huang, Y., Li, Z., Wu, Y., Zhu, X., Liu, P., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.099747 · Cited by 33
Hu, J., Huang, Y.-D., Pan, T., Zhang, T., Su, T., Li, X., Luo, H., & Huang, L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00376 · Cited by 33
Lajarín-Cuesta, R., Nanclares, C., Arranz-Tagarro, J.-A., González‐Lafuente, L., Arribas, R. L., de Brito, M. A., Gandía, L., & Ríos, C. D. L. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00478 · Cited by 32
Wu, M., Ma, J., Ji, L., Wang, M., Han, J., & Li, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.055 · Cited by 32
Brindisi, M., Brogi, S., Maramai, S., Grillo, A., Borrelli, G., Butini, S., Novellino, E., Allarà, M., Ligresti, A., Campiani, G., et al. (2016) · RSC Advances · doi:10.1039/c6ra12524g · Cited by 30
Self-citationDevelopment of novel cyclic peptides as pro-apoptotic agents
Brindisi, M., Maramai, S., Brogi, S., Fanigliulo, E., Butini, S., Guarino, E., Casagni, A., Lamponi, S., Bonechi, C., Nathwani, S. M., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.04.001 · Cited by 27
Self-citationBrindisi, M., Borrelli, G., Brogi, S., Grillo, A., Maramai, S., Paolino, M., Benedusi, M., Pecorelli, A., Valacchi, G., Mannelli, L. D. C., et al. (2018) · ChemMedChem · doi:10.1002/cmdc.201800397 · Cited by 27
Self-citationGao, C.-Z., Dong, W., Cui, Z.-W., Yuan, Q., Hu, X.-M., Wu, Q.-M., Han, X., Xu, Y., & Min, Z.-L. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1530224 · Cited by 27
Sagar, S. R., Singh, D. P., Das, R. D., Panchal, N. B., Sudarsanam, V., Nivsarkar, M., & Vasu, K. K. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102992 · Cited by 27
Marcinkowska, M., Bucki, A., Panek, D., Siwek, A., Fajkis-Zajączkowska, N., Bednarski, M., Zygmunt, M., Godyń, J., Valdivieso, Á. D. R., Kotańska, M., et al. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201900041 · Cited by 27
Phenylpyrrole-Based Hdac Inhibitors: Synthesis, Molecular Modeling and Biological Studies
Brindisi, M., Cavella, C., Brogi, S., Nebbioso, A., Senger, J., Maramai, S., Ciotta, A., Iside, C., Butini, S., Lamponi, S., et al. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0068 · Cited by 22
Self-citationYabuki, Y., Matsuo, K., Hirano, K., Shinoda, Y., Moriguchi, S., & Fukunaga, K. (2017) · Pharmacology · doi:10.1159/000452839 · Cited by 22
Sagar, S. R., Singh, D. P., Panchal, N. B., Das, R. D., Pandya, D. H., Sudarsanam, V., Nivsarkar, M., & Vasu, K. K. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00063 · Cited by 22
Gabr, M. T., & Abdel‐Raziq, M. S. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.07.019 · Cited by 21
Self-citationSynthesis and SAR of tolylamine 5-HT6 antagonists
Singer, J. M., Wilson, M. W., Johnson, P. D., Graham, S. R., Cooke, L. W., Roof, R. L., Boxer, P. A., Gold, L. H., Meltzer, L. T., Janssen, A. M., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.077 · Cited by 19
Butini, S., Gemma, S., Brindisi, M., Maramai, S., Minetti, P., Celona, D., Napolitano, R., Borsini, F., Cabri, W., Fezza, F., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.11.035 · Cited by 17
Self-citationBrogi, S., Maramai, S., Brindisi, M., Chemi, G., Porcari, V., Corallo, C., Gennari, L., Novellino, E., Ramunno, A., Butini, S., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700551 · Cited by 15
Self-citationRasagiline derivatives combined with histamine H3 receptor properties
Lutsenko, K., Hagenow, S., Affini, A., Reiner‐Link, D., & Stark, H. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.08.016 · Cited by 15
Nuñez‐Borque, E., González-Naranjo, P., Bartolomé, F. B., Alquézar, C., Reinares-Sebastián, A., Pérez, C., CEBALLOS, M. L. D., Paez, J. A., Campillo, N. E., & Martín‐Requero, Á. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01813-4 · Cited by 14
Gonzalez, D., Arribas, R. L., Viejo, L., Lajarín-Cuesta, R., & Ríos, C. D. L. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.019 · Cited by 10
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Superoxide dismutase as multipotent therapeutic antioxidant enzyme: Role in human diseases
Saxena, P., Selvaraj, K., Khare, S. K., & Chaudhary, N. (2022) · Biotechnology Letters · doi:10.1007/s10529-021-03200-3 · Cited by 160
Niewiadomska, G., Niewiadomski, W., Steczkowska, M., & Gasiorowska, A. (2021) · Life · doi:10.3390/life11010028 · Cited by 131
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Walgrave, H., Zhou, L., De Strooper, B., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 131
Rehman, M. U., Sehar, N., Dar, N. J., Khan, A., Arafah, A., Rashid, S., Rashid, S. M., & Ganaie, M. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104961 · Cited by 130
Metadata
- Authors
- Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S.
- Affiliations
- University of Siena (IT)
- Conservatoire National des Arts et Métiers (FR)
- Stanford Medicine (US)
- Helmholtz Institute for Pharmaceutical Research Saarland (DE)
- Corresponding author
- Maramai, Samuele
- Yahiaoui, Samir
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2020-01
- Volume
- 2020
- Issue
- 1
- Pages
- 5120230-5120230
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC7354643
- OpenAlex
- W3039786831
- Cited by
- 121
- References
- 145
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 20 · 2023: 17 · 2022: 29 · 2021: 22 · 2020: 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion, cc-by-nc-sa)
- Use Siena air (University of Siena) (submittedVersion, cc-by)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, multi-target-directed ligands, multi-target therapy, neurodegeneration, protein aggregation, oxidative stress, neuroinflammation, neuroprotection, metal homeostasis, drug discovery, animal models of dementia
- MeSH terms
- Alzheimer Disease, Animals, Humans, Ligands, Oxidative Stress, Neuroprotective Agents, Molecular Targeted Therapy, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.